Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">On The Wires<ul><li>Mitek (<strong>MITK</strong>) announced that a top crowdfunding platform selected Mitek's Mobile Verify to improve their new user on-boarding experience and help the company meet Know Your Customer and anti-money laundering requirements.</li><li>Chevron Corporation (<strong>CVX</strong>) announced that its subsidiary, Cabinda Gulf Oil Company Limited, has commenced oil and gas production from the main production facility of the Mafumeira Sul project offshore Angola.</li><li>As previously reported, on July 27, 2016, the United States District Court for the District of Massachusetts dismissed the suit brought by Amphastar Pharmaceuticals (<strong>AMPH</strong>) and its wholly-owned subsidiary International Medication Systems Ltd. against Momenta Pharmaceuticals, Inc. (<strong>MNTA</strong>) and Sandoz Inc. (Novartis (<strong>NVS</strong>) unit) alleging that, in connection with filing the September 2011 patent infringement suit against Amphastar and Actavis (Teva (<strong>TEVA</strong>) unit), the Company and Sandoz sought to prevent Amphastar from selling generic Enoxaparin Sodium Injection and thereby exclude competition for generic Enoxaparin Sodium Injection in violation of federal and California anti-trust laws and California unfair business laws. Also as previously reported, on August 25, 2016, Amphastar filed a notice of appeal from the dismissal with the United States Court of Appeals for the First Circuit. On March 6, 2017, the United States Court of Appeals for the First Circuit reversed the District Court's dismissal and remanded the suit to the District Court for further proceedings.</li></ul></td> </tr></table>"